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ABSTRACT
Objective: The objective of this study was to compare the cost-effectiveness of 3 strategies of serologic
enzyme-linked immunosorbent assay (ELISA) testing and post-exposure varicella zoster immune globulin
(VZIG) prophylaxis for the prevention of maternal varicella pneumonia during pregnancy in patients with
negative or uncertain histories of varicella infection.
Methods: A decision tree was constructed to compare the following strategies: 1) routine serologic testing
for varicella immunity followed by targeted post-exposure VZIG prophylaxis, 2) post-exposure serologic
testing followed by targeted VZIG prophylaxis, and 3) untargeted post-exposure VZIG administration. The
probabilities for the model were obtained from the medical literature and supplemented by expert opinion.
The costs were obtained by a review of inpatient hospitalizations for varicella pneumonia. All costs were
converted to 1995 dollars.
Results: Routine serologic testing followed by targeted post-exposure VZIG prophylaxis was the most
costly strategy ($37.22/person), with no demonstrable increase in benefit compared with the other 2 strate-
gies. The disutility of this strategy compared with the others was stable across a wide range of values for
the probabilities and costs utilized in the sensitivity analysis. We were unable to differentiate between the
cost-effectiveness of the other 2 strategies.
Conclusions: Routine serologic testing for varicella immunity in patients with negative or uncertain
histories of varicella infection should not be performed. The remaining options of screening and prophylaxis
appear to be reasonable alternatives for dealing with varicella exposures. (C) 1996 Wiley-Liss, Inc.
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aricella (chickenpox) is a highly contagious viral
illness usually acquired in childhood. Previous
studies have shown that 90-95% of adults born in
North America are serologically immune. While
the disease is mild in childhood, it can cause signifi-
cant morbidity in adults. In addition, these infec-
tions are believed to be especially severe during
pregnancy because of alterations in the maternal
immune status. Varicella infection in pregnancy has
been associated with preterm labor, congenital mal-
formations, and maternal pneumonia, z’3 Pneumonia
is the most common complication in adults, with a
mortality rate approaching 25%. While the actual
number of cases of maternal varicella pneumonia
is small, the severity of this disease warrants inter-
ventions and strategies for prevention.
The administration of varicella zoster immune
globulin (VZIG)within 96 h of exposure has been
shown to prevent or ameliorate the effects of vari-
cella infection in susceptible individuals. Although
VZIG does not appear to prevent congenital infec-
tion, many experts have recommended the adminis-
tration of VZIG to all susceptible pregnant women
exposed to varicella-infected individuals in order to
prevent the complications associated with over-
whelming maternal infection. There are several dif-
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ficulties in practice with this recommendation.
First, the susceptibility must be ascertained accu-
rately within a short time if VZIG is to be given
within 96 h after exposure. Such rapid testing is not
available in most areas. Second, VZIG is difficult
to obtain and is perceived as "expensive." As such,
physicians are unlikely to prescribe this medication
unless a lack of immunity is relatively certain. Be-
cause ofthese problems, several authors have evalu-
ated the patient history as a predictor of true sero-
logic immunity. 5’6 It has been demonstrated that a
positive maternal history of varicel!a infection reli-
ably predicts true serologic immunity.
5,6 However,
in patients with negative or uncertain histories, the
relationship to true immune status is less reliable.
Thus, there are several obvious options for dealing
with varicella exposure in patients with negative or
uncertain histories of varicella infection:
1. Routine serologic [enzyme-linked immunosor-
bent assay (ELISA)] screening at the initial pre-
natal visit, followed by targeted post-exposure
VZIG administration.
2. Post-exposure serologic testing, followed by tar-
geted VZIG administration.
3. Untargeted post-exposure VZIG administration.
In cases of clinical and economic uncertainty, a
cost-effectiveness analysis can be a useful tool in
guiding clinical practice.7’SThe purpose of this study
was to apply this methodology to the comparison
ofthe above strategies for the prevention ofvaricella
pneumonia in patients with negative or uncertain
histories of varicella infection.
MATERIALS AND METHODS
A decision tree was created to compare the options
of 1) routine varicella ELISA testing, 2) post-expo-
sure testing with targeted VZIG administration, and
3) untargeted post-exposure VZIG administration
in pregnant patients with negative or uncertain his-
tories of varicella infection. This decision tree was
created and analyzed using Data 2.5 software
(TreeAge Software, Boston, MA).
Strategies
A graphic representation of the 3 strategies is shown
in Figure 1.
Strategy
In the strategy of routine varicella ELISA testing,
we assumed that every patient with a negative or an
uncertain history of infection would have a varicel!a-
titer determination at the initial prenatal visit. In
the case of a patient exposed to a varicella-infected
person ("household" contact), we assumed that a
patient with a positive titer would not receive
VZIG, while a patient with a negative titer would
receive VZIG.
Strategy 2
In the strategy of post-exposure testing with tar-
geted VZIG administration, we assumed that a pa-
tient would not have a varicella ELISA unless she
was exposed to a varicella-infected individual
("household" contact). In the latter case, we as-
sumed that a patient with a positive titer would not
receive VZIG, while a patient with a negative titer
would receive VZIG. We also assumed that the
results of the varicella ELISA would always be
available quickly enough for the administration of
VZIG within 96 h of exposure.
Strategy 3
In the strategy of untargeted post-exposure VZIG
administration, we assumed that no patient would
ever be tested for varicella immunity even if she
was exposed to an infected individual. In this strat-
egy, we assumed that all patients with negative
or uncertain histories exposed to varicella-infected
individuals would receive VZIG empirically. We
also assumed that VZIG would always be given
within 96 h of exposure.
Probabilities
The probabilities and ranges for this decision tree
were obtained from a review of the pertinent litera-
ture (Table 1).3-6.9-22 While several of these probabil-
ity estimates are based on data from several decades
ago,z,4,14-17 they represent the best estimates of these
probabilities available. We also used wide ranges
for these probabilities in our sensitivity analysis to
account for this uncertainty. For the efficacy of
VZIG, we sought expert opinions from subspecial-
ists in infectious disease because of a lack of precise
data on VZIG efficacy in pregnancy. To evaluate
the role of uncertainty for this probability, we used
a wide range for this probability estimate in our
sensitivity analysis.
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TABLE I. Probabilities for the model
Base case Range
Serologic immunitys’6
Varicella exposure9’
ELISA sensitivity
ELISA specificity
4,s
Varicella after exposure ("household" contact) 4’ls
Varicella pneumonia/-VZlG3’6-19
Varicella pneumonia/-I-VZlG4’2-22
0.65 0.55-0.80
0.0005 0.000 I-0.02
0.87 0.70-0.97
0.90 0.84-1.00
0.80 0.70-0.95
0.10 0.05-0.30
0.05 0.01-0.20
Costs
The cost of a varicella ELISA was based upon an
average of the costs from several laboratories in the
Philadelphia area. The cost of an average dose of
VZIG was ascertained from the hospital pharmacy
billing system. To obtain information about the cost
of impatient hospitalization for varicella pneumo-
nia, we conducted a medical-record search for the
years 1984-1994 using ICD-9-CM codes for vari-
celia pneumonia cross-linked to the codes for preg-
nancy. The charts identified with this search strat-
egy were then briefly reviewed to ascertain the
accuracy about diagnosis and pregnancy status. The
charts of patients with underlying immune suppres-
sion were excluded. The inpatient charges for these
patients were then obtained. Since these admis-
sions were over a 10-year period, all dollars were
converted to 1995 dollars by using a hospital-spe-
cific inflation factor. All charges were converted to
cost by using a hospital-specific cost:charge ratio.
Outcomes and Analysis
By folding back our decision tree for each of the 3
strategies, we calculated the average direct cost per
patient and the percentage of cases of varicella
pneumonia prevented for the specific strategy.
Since we assumed the efficacy ofVZIG to be 50%,
no strategy could be perfectly effective in pre-
venting varicella pneumonia. The best strategy
would be the one with the lowest cost per patient
and the highest percentage of cases of varicella
pneumonia prevented. To test the impact of the
plausible ranges of probabilities and costs on the
clinical decision, we performed multiple one- and
two-way sensitivity analyses.
RESULTS
The baseline estimates, ranges, and references for
the various probabilities used in the model are listed
TABLE 2. Costs used in the model
Base case Range
Varicella ELISA $37 $21-77
VZIG $283 $120-560
Varicella pneumonia $43,644 $8,420-112,427
in Table 1. Our medical-record search revealed 8
patients with varicella pneumonia, none of whom
were excluded from our cost calculation. The base-
line cost (Table 2) for this disease was the average
of the charges for the 8 patients. The range used
in the sensitivity analysis included the lowest and
highest charges for an individual patient.
Overall, routine serologic testing (strategy 1) was
the costliest option ($37.22/patient). Moreover, no
additional benefit in the prevention of varicella
pneumonia was associated with this strategy com-
pared with the other strategies (Table 3). This re-
sult was stable across the range of plausible proba-
bilities and costs utilized for the one- and two-way
sensitivity analyses, meaning that routine serologic
screening was never the preferred strategy under
any circumstance. This result is clearly driven by
the low exposure rate to varicella in pregnancy.
However, even when the probability of exposure
was varied over an extremely wide range, this dis-
utility for strategy persisted. Thus, routine screen-
ing should not be employed. This analysis of the
impact of the exposure rate on the clinical decision
also suggested that our results are generalizable to
groups of individuals with higher exposure rates,
e.g., women with occupational exposures or chil-
dren in the home.
Post-exposure testing with targeted VZIG (strat-
egy 2) and untargeted post-exposure VZIG admin-
istration (strategy 3)were very similar with regard to
the average cost per patient and expected benefit,
although strategy 3 would prevent approximately
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TABLE 3. Cost per patient and effectiveness of strategies
Strategy Strategy 2 Strategy 3
Serologic testing All
Post-exposure VZIG Selective
Cost per patient $37.22
% of varicella pneumonia prevented 47
Post-exposure None
Selective All
$0.19 $0.24
47 50
3% more cases of pneumonia. This difference in
effectiveness is related to the imperfect test charac-
teristics for varicella serologic testing. The differ-
ences between these 2 options were sensitive to
many of the assumptions in our model, including
the probability of exposure, probability of serologic
immunity, and cost of disease. As we could not
differentiate between the cost-effectiveness of
these latter 2 strategies with our model, either strat-
egy appears reasonable.
DISCUSSION
The clinical scenario in which a potentially suscep-
tible pregnant woman is exposed to varicella is of
great concern to both the patient and her physician.
For this reason, some investigators have suggested
that a varicella ELISA screen be added to routine
prenatal testing in women with negative or uncer-
tain histories of varicella infection. Our analysis
clearly demonstrated that routine screening was
dominated by the other options in that it was the
most costly strategy with no additional benefit com-
pared with the other strategies. The model was
robust in that "routine screening" was never a pre-
ferred strategy across the ranges used in any of the
sensitivity analyses. For this reason, this strategy
should not be employed.
The strategies of post-exposure serologic testing
with selective treatment and empiric post-exposure
prophylaxis were similar in both cost and clinical
benefit, although empiric prophylaxis would pre-
vent approximately 3% more cases of varicella
pneumonia. This small difference in clinical benefit
is related to the imperfect test characteristics of
varicella ELISA testing. The small difference be-
tween these 2 strategies was sensitive to many ofthe
assumptions examined in the sensitivity analysis.
Thus, we are unable to make specific recommenda-
tions regarding these 2 options. Still, for the many
areas where rapid testing is not available, empiric
post-exposure treatment is the most cost-effective
of the remaining 2 options.
Several assumptions of importance for interpre-
tation were made in this model. First, there were
no reports of controlled trials evaluating the efficacy
ofVZIG in pregnant women. We chose to use both
the available evidence in nonpregnant patients sup-
plemented by expert opinions from infectious dis-
ease specialists to estimate the efficacy of treat-
ment. We also chose a wide range of values for
use in the sensitivity analysis. Second, the cost was
ascertained by a review of the inpatient admissions
for varicella pneumonia, which possibly overesti-
mates the true cost because not all cases ofpneumo-
nia will result in hospitalization. Again, even with
a wide range ofvalues chosen for the cost of disease,
the principal conclusions of our study were un-
changed in the sensitivity analysis. Third, we as-
sumed that VZIG was not associated with any se-
vere adverse effects. While there have been no
reports of the transmission of infectious agents with
VZIG, such an occurrence might dramatically
change our results. Fourth, we assumed that VZIG
did not prevent the congenital varicella syndrome,
which is estimated to occur in 4% of first-trimester
infections. This assumption is based on several case
reports of this syndrome in infants of mothers
treated with VZIG. However, there may be a clini-
cal benefit to the fetus which has not yet been elu-
cidated.
We did not consider the utility of the varicella
vaccine in our analysis. While this vaccine is not
recommended for use during pregnancy, a program
of universal screening of adults (or of reproductive-
age women alone) may be a cost-effective strategy.
Questions about the long-term effectiveness of the
vaccine in adults make this possibility speculative.
In summary, our study demonstrates that univer-
sal screening for varicella immunity followed by
post-exposure treatment with VZIG in patients
with negative or uncertain histories should not be
performed. The choice between the other clinical
strategies should be based on the availability of
rapid serologic testing for varicella immunity.
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